The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Mesoblast Limited (MESO)

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Kristal v. Mesoblast Limited, et al., (Case No. 1:20-cv-08430), on behalf of persons and entities that purchased or otherwise acquired Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) securities between April 16, 2019 and October 1, 2020, inclusive (the “Class Period”). Plaintiff pursues under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”)

If you are a shareholder who suffered a loss, click here to participate.

Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform. Its lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow. In February 2018, the Company announced that remestemcel-L met its primary endpoint in a Phase 3 trial

Read More

The Law Offices of Frank R. Cruz Continues Its Investigation of Mesoblast Limited (MESO) on Behalf of Investors

The Law Offices of Frank R. Cruz continues its investigation of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On October 1, 2020, the Company disclosed that it had received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its marketing application for remestemcel-L for treatment of SR-aGVHD in pediatric patients. According to the CRL, the FDA recommended that Mesoblast “conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD.” The CRL also “identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the product’s biologic activity.”

On this news, Mesoblast’s stock fell $6.53, or 35%, to close at $12.03 per

Read More

The Law Offices of Frank R. Cruz Announces Investigation of Mesoblast Limited (MESO) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On October 1, 2020, the Company disclosed that it had received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its marketing application for remestemcel-L for treatment of SR-aGVHD in pediatric patients. According to the CRL, the FDA recommended that Mesoblast “conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD.” The CRL also “identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the product’s biologic activity.”

On this news, Mesoblast’s stock fell $6.53, or 35%, to close at $12.03 per

Read More

The Folio Society is Releasing a Limited, Special Edition of Frank Herbert’s Dune

Five years ago, the Folio Society began regularly releasing science fiction novels in its lineup of high-end collectors editions, starting with Frank Herbert’s Dune.

With the film adaptation coming out this December, the publisher has announced a new special edition of the book, which goes above and beyond its already beautiful previous edition.

The Folio Society has been around for more than 50 years, and started out as a subscription business for bibliophiles. It re-released prominent literary classics, often with specially-commissioned art, introductions, or afterwords, and a handsome slipcase. While they had published the occasional science fiction and fantasy novel over the years—like Isaac Aimov’s Foundation trilogy, Philip Pullman’s His Dark Materials, or J.R.R. Tolkien’s Lord of the Rings, their release of Dune brought about a regular release of some of the best-known works of science fiction and fantasy, including authors like Ray Bradbury, Octavia Butler, Arthur

Read More

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of HDFC Bank Limited (HDB) Investors

LOS ANGELES, Sept. 28, 2020 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired HDFC Bank Limited (“HDFC Bank” or the “Company”) (NYSE: HDB) securities between July 31, 2019 and July 10, 2020,  inclusive (the “Class Period”). HDFC Bank investors have until November 2, 2020 to file a lead plaintiff motion.

(PRNewsfoto/The Law Offices of Frank R. Cru)
(PRNewsfoto/The Law Offices of Frank R. Cru)

If you are a shareholder who suffered a loss, click here to participate.

On July 13, 2020, media reported that HDFC Bank had “conducted a probe into allegations of improper lending practices and conflicts of interests in its vehicle-financing operations involving the unit’s former head.”

On this news, HDFC Bank’s American depositary receipt price fell $1.37 per share, or nearly 3%, to close at $47.02 per share on July

Read More